Daniel James Hodson

机构：Guy's and St Thomas' NHS Foundation Trust, Wellcome/MRC Cambridge Stem Cell Institute, University of Cambridge, Fundació Clínic per a la Recerca Biomèdica, Cambridge Clinical Trials Unit · ORCID：0000-0001-6225-2033

发表论文 221 篇 · 总被引 6624 次 · h-index 30

代表论文

• The long-term effects of chemotherapy on normal blood cells (2025 · Nature Genetics · 被引 45)
• RNA binding proteins control the G 2 -M checkpoint of the germinal center B cell (2025 · Science Immunology · 被引 10)
• Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study (2025 · Journal of Clinical Oncology · 被引 9)
• Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study (2026 · Blood · 被引 5)
• MCL-1493: Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL) (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 3)
• Enforced MYC expression directs a distinct transcriptional state during plasma cell differentiation (2025 · Life Science Alliance · 被引 2)